Shamburg News · 8-K filed Nov 12, 2026, 7:11 AM EST

Absci Reports Third Quarter 2026 Results and ABS-201 Program Updates

ABSI · Absci Corp

  • Earnings
  • Other event
  • Materiality: high

Absci Corporation reported unaudited third quarter 2026 results, with partner program revenue of $304 thousand and a net loss of $33.3 million, or $0.19 per basic and diluted share, for the quarter ended September 30, 2026. Research and development expenses were $23.6 million and cash, cash equivalents, and marketable securities totaled $173.7 million at quarter end. The company also updated its ABS-201 pipeline, stating it expects 13-week interim proof-of-concept data for pattern hair loss in December 2026 and planned a Phase 2 endometriosis trial for mid-2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 8.01, accession 0001672688-26-000150.

Written from the filing by Shamburg Markets. Figures are as reported by the company.